AbbVie (prior sponsor, Abbott)

Quick facts

Phase 3 pipeline

• ABT-267 · Immunology / Inflammation
  ABT-267 is a selective inhibitor of the chemokine receptor CCR2 that reduces monocyte recruitment to sites of inflammation.
• ABT-333 · Virology / Hepatology
  ABT-333 is a non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase that blocks viral replication.
• ABT-450/r/ABT-267, ABT-333 · Virology / Hepatology
  This combination of hepatitis C virus (HCV) protease inhibitors and a non-nucleoside polymerase inhibitor blocks viral replication by inhibiting essential HCV enzymes.
• ABT-450/ritonavir · Virology / Hepatology
  ABT-450 is a hepatitis C virus NS3/4A protease inhibitor that blocks viral replication, boosted by ritonavir to increase drug levels.
• ABT-712 · Oncology
  ABT-712 is a selective inhibitor of fibroblast growth factor receptor 1 (FGFR1) that blocks aberrant signaling in cells dependent on FGFR1 activation.
• Leuprolide Acetate 3 Month Depot · Oncology; Endocrinology
  Leuprolide acetate is a gonadotropin-releasing hormone (GnRH) agonist that suppresses luteinizing hormone and follicle-stimulating hormone, leading to decreased testosterone and estrogen production.
• Open-label Adalimumab · Immunology
  Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
• Placebo for ABT-333
  A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
• Placebo for ABT-450/r/ABT-267 · Hepatology
  This is a placebo control with no active pharmacological mechanism.
• Placebo (PBO) oral capsules
  Placebo contains no active pharmaceutical ingredient and produces therapeutic effects solely through the placebo effect—the patient's expectation of benefit.

Phase 2 pipeline

• ABT-288 High Dose · Diabetes
  ABT-288 High Dose is a glucagon receptor antagonist.
• ABT-288 Low Dose
• ABT-450 · Infectious Diseases
  ABT-450 is a protease inhibitor that works by blocking the replication of the hepatitis C virus.
• ABT-652 · Immunology / Respiratory
  ABT-652 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
• ABT-652 NSAID
• ABT-806
• ABT-888 · Oncology
  ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes.
• ABT-894 · Multiple Sclerosis, Autoimmune Diseases
  ABT-894 is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).
• ABT-981
• Adalimumab, current formulation · Immunology
  Tumor necrosis factor-alpha inhibitor
• Adalimumab, new formulation · Immunology
  Adalimumab is a monoclonal antibody that binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine.
• Atrasentan high dose group · Cardiovascular
  Atrasentan is an endothelin receptor antagonist that blocks the action of endothelin-1, a potent vasoconstrictor.
• Atrasentan low dose group · Cardiovascular
  Endothelin receptor antagonist
• New formulation adalimumab

Phase 1 pipeline

• ABT-348
• ABT-348 and azacitidine · Oncology
  AZA is a hypomethylating agent that targets DNA methyltransferase enzymes.
• ABT-348 and carboplatin
• ABT-348 and docetaxel · Oncology
  Docetaxel is a microtubule inhibitor that works by stabilizing microtubules and preventing cell division.
• ABT-700
• ABT-767

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• AbbVie (prior sponsor, Abbott) portfolio CI brief
• AbbVie (prior sponsor, Abbott) pipeline updates RSS

Frequently asked questions about AbbVie (prior sponsor, Abbott)

Related

• Sector hub: All tracked pharma companies